The Efficacy and Safety of Riamilovir in the Treatment of Patients with COVID-19
https://doi.org/10.37489/0235-2990-2021-66-1-2-33-37
Abstract
Aim. Evaluation of the efficacy, safety, and tolerability of Riamilovir (trade name «Triazavirin®») in patients with mild COVID-19.
Materials and methods. The randomized open-label study included 120 patients with clinical and epidemiological manifestations of coronavirus infection and its laboratory (PCR) confirmation.
Results. The efficacy, safety, as well as good tolerability of Riamilovir in the treatment of new coronavirus infection (COVID-19) have been established.
Conclusion. The results of the study on the efficacy, safety, and tolerability of Riamilovir allow us to recommend it as a means of etiotropic therapy of the new coronavirus infection (COVID-19).
About the Authors
А. U. Sabitov
Ural State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Alebay U. Sabitov — D. Sci. in Medicine, professor
Yekaterinburg
Р. V. Sorokin
OOO «Azol Pharma», Novouralsk
Russian Federation
Russian Federation
Pavel V. Sorokin — Ph. D. in Pharmacy
S. U. Dashutina
City Clinical Hospital No. 14
Russian Federation
Russian Federation
Svetlana U. Dashutina —Ph. D. in Medicine
Yekaterinburg
References
1. Vremennye metodicheskie rekomendatsii Ministerstva zdravookhraneniya Rossii «Profilaktika, diagnostika i lechenie novoj koronavirusnoj infektsii (COVID-19)», versiya 10, 08.02.2021. (in Russian)
2. Tokin I.I., Zubkova T.G., Drozdova Jyu.V., Lioznov D.A. Opyt etiotropnoj terapii ORVI otechestvennym protivovirusnym preparatom. Infektsionnye Bolezni. 2019; 17 (4): 13–17. doi: 10.20953/1729-9225-2019-4-13-17 (in Russian)
3. Lioznov D.A., Tokin I.I., Zubkova T.G., Sorokin P.V. Praktika primeneniya otechestvennogo protivovirusnogo preparata v etiotropnoj terapii ostroj respiratornoj virusnoj infektsii. Terapevticheskij arkhiv. 2020; 92 (12): 59– 63. doi: 10.26442/00403660.2020.12.200427 (in Russian)
4. Xiaoke Wu, etc. The Efficacy and Safety of Triazavirin for COVID-19: A trial protocol. Engineering, 07, 2020.
5. Xiaoke Wu, etc. Efficacy and Safety of Triazavirin therapy for Coronavirus disease 2019: a pilot randomized controlled trial, 09, 2020.
6. Sabitov A.U., Belousov V.V., Edin A.S., Olejnichenko E.V., Gladunova E.P., Tikhonova E.P., Kuz'mina T.Jyu., Kalinina Jyu.S., Sorokin P.V. Prakticheskij opyt primeneniya preparata Riamilovir v lechenii patsientov s COVID-19 srednej stepeni tyazhesti. Antibiotiki i Khimioter. 2020; 65 (7–8): 27–30. doi: 10.37489/0235-2990-2020-65-7-8-27-30 (in Russian)
7. Kas'yanenko K.V., Mal'tsev O.V., Kozlov K.V., Lapikov I.I., L'vov N.I., Sukachev V.S., Zhdanov K.V., Sorokin P.V., Ratnikova A.K. Klinicheskaya effektivnost' i bezopasnost' primeneniya Riamilovira pri lechenii patsientov s infektsiej, vyzvannoj SARS-CoV-2. Antibiotiki i khimioter. 2020; 65: (11–12): 16–21. doi: 10.37489/0235-2990-2020-6511-12-16-21 (in Russian)
8. Klinicheskij protokol lecheniya bol'nykh novoj koronavirusnoj infektsiej COVID-19, nakhodyashchikhsya na statsionarnom lechenii v meditsinskikh organizatsiyakh gosudarstvennoj sistemy zdravookhraneniya goroda Moskvy (https://mosgorzdrav.ru/professional/covid-19). (in Russian)
9. Klinicheskij protokol lecheniya bol'nykh novoj koronavirusnoj infektsiej COVID-19, nakhodyashchikhsya na statsionarnom lechenii v meditsinskikh organizatsiyakh gosudarstvennoj sistemy zdravookhraneniya goroda Moskvy (https://mosgorzdrav.ru/professional/covid-19). (in Russian)
Review
For citations:
Sabitov А.U., Sorokin Р.V., Dashutina S.U. The Efficacy and Safety of Riamilovir in the Treatment of Patients with COVID-19. Antibiot Khimioter = Antibiotics and Chemotherapy. 2021;66(1-2):35-37. (In Russ.) https://doi.org/10.37489/0235-2990-2021-66-1-2-33-37
Views:
3136
Email this article 